Introduction
Carcinoma of the cervix remains the most frequent cancer a ecting women in South Africa. Twenty-three per cent of all reported cancers in women are of the uterine cervix. Cancer of the cervix resulted in an estimated 3 700 deaths in South Africa during 2002.
The human papillomavirus (HPV) has been proven a potent carcinogen. The aetiological role of HPV infection in the development of preinvasive and invasive lesions of the cervix, vagina and the anogenital region has been conclusively established. Vaccination against infection with speci c high-risk HPV is commercially available, and is likely to change the future of the disease.
Epidemiology and burden of disease
The HPV types most commonly associated with the development of malignant disease include HPV16 and HPV18 and, to a lesser degree, HPV31 and HPV45. HPV types are classi ed as high and low risk according to their association with cancer. The ve most frequent HPV types among women with cervical cancer are HPV16, HPV18, HPV33, HPV45 and HPV31.
Low-risk HPV (mainly HPV6 and HPV11) causes approximately 90% of genital warts, and there is possibly an aetiological association with recurrent juvenile laryngeal papillomatosis.
Preventing cervical cancer

Primary prevention
HPV infection is one of the most common sexually transmitted infections worldwide, a ecting more than 70% of women in the USA and up to 95% of high-risk women in Africa.
Prophylactic HPV vaccines, protecting against certain oncogenic strains, are available and represent the most important advance in the ght against cervical cancer, as a primary preventative strategy.
Other factors include the reduction of smoking, both active and passive, to prevent cervical cancer. Recently, two other important additional strategies have also been shown to be of value. The use of condoms has been shown to signi cantly decrease the incidence of acquiring HPV infection. Condom use will decrease HPV infection by about 60%, but it will not eradicate infection totally. Of note is that HPV infection of the anogenital area does not only depend on penetrative sex, and that purely skin-to-skin contact is su cient to cause infection. The other important strategy is male circumcision. This signi cantly decreases transmission of HPV from males to females.
Secondary prevention
Secondary prevention is aimed at screening the general population to identify those individuals at high risk of developing disease. Cervical cytology has been the most successful cancer prevention strategy in history, and has signi cantly reduced the number of new cases of invasive carcinoma. The sensitivity and speci city of a single cytology test are, however, often disappointingly low. Well-organised call and recall programmes are expensive. In South Africa, the national cytology programme has not had any signi cant impact on mortality statistics, and may never be successful in certain isolated populations with poor access to health care.
High-risk HPV testing o ers several potential advantages over conventional cervical cytology in the setting of primary screening, but also has many limitations. HPV testing is signi cantly more sensitive than cytology in predicting cervical cancer and its precursors. It is apparent that HPV testing may be a better test to use in programmes with once-in-alifetime testing or long screening intervals (> 5 years). Longer screening intervals are more cost-e ective, overall.
Other strategies include visual inspection of the cervix after acetic acid application (VIA), which has a sensitivity of 67-79% and a speci city of 49-86%, and visual inspection of the cervix after Lugol's iodine application (VILI), which has a sensitivity of 78-98% and a speci city of 73-93%.
Prophylactic HPV vaccination
The human papaillomavirus HPV is a non-enveloped, double-stranded, deoxyribonucleic acid (DNA) virus. The genome of HPV is enclosed in a capsid shell made up of major (L1) and minor (L2) structural proteins. There are more than 100 known genotypes of HPV, and certain (oncogenic) types are associated with cell transformation that leads to cancer. Certain high-risk HPV viruses have an a nity for integrating certain areas of the viral genome into the host chromosomes.
Pathology and immunology
HPV gains access to cervical tissue via skin abrasions and invades the basal layer, where it resides for the long term. A large percentage of the population will have sustained clinical remission, but a small proportion will develop persistent infection and become HPV-DNA positive on repeated testing. Persistent infection with oncogenic strains of HPV can lead to high-grade squamous intraepithelial neoplasia or adenocarcinoma in situ (AIS). These precancerous lesions have a high probability of progressing to invasive squamous carcinoma or adenocarcinoma.
HPV infection a ects the intraepithelial layer of the mucosa, and does not elicit a marked immune response. About 50% of women infected with HPV develop detectable serum antibodies, although these antibodies are not necessarily protective against subsequent reinfection by the same HPV type.
Prophylactic HPV vaccine
HPV virus-like particles (VLP) are used in the manufacturing of the currently available prophylactic vaccines. These vaccines contain no viral DNA capable of replication and are, therefore, non-infectious and cannot lead to disease. They induce antibody titres much higher than naturally occurring infections. The VLPs are combined with a non-speci c immune stimulant called an adjuvant, which leads to improved production of immunoglobulins against the vaccine types of VLPs. These speci c antibodies must be concentrated primarily within the cervicovaginal secretions to ultimately provide protection.
Currently, there are two registered prophylactic vaccines for HPV vaccination, namely Cervarix®, which contains HPV types 16 and 18, and Gardasil®, which protects against HPV16, HPV18 and low-risk types 6 and 11.
E cacy
The quadrivalent prophylactic vaccine (Gardasil®) has been evaluated in two phase III randomised placebocontrolled clinical trials designed to investigate its e cacy. In women who had no prior evidence of infection, the vaccine was 98.2% e ective at 3.6 years against HPV16 and HPV18 cervical intraepithelial neoplasia (CIN) 2 or 3 lesions and adenocarcinoma in situ lesions. Gardasil® was 100% e ective against HPV6-and HPV11-related lesions. The quadrivalent vaccine also showed partial cross-protection to other vaccine types. There was also a signi cant reduction in colposcopy, cervical biopsy and de nitive therapy.
The e cacy of the bivalent vaccine (Cervarix®) for protection against HPV16 and HPV18 CIN 2 lesions was 98.4%, and against HPV16-and HPV18-associated CIN 3 lesions it was 100%. There was also signi cant protection against non-vaccine oncogenic types [HPV33 (72.3%) and HPV45 (100%)]. The bivalent vaccine signi cantly decreased colposcopy referrals and cervical excision procedures.
Safety
The safety of the two HPV vaccines has been studied extensively during clinical trials. This has been closely monitored by governing bodies, including the Centers for Disease Control and Prevention (CDC) and the FDA (Food and Drug Administration) in the United States. The overwhelming opinion, from all the published data, is that both commercial HPV vaccines are extremely safe, without any proven serious risks.
Non-serious events associated with HPV vaccination include fainting, pain and swelling at the injection site, headache, nausea and fever. There is no increase in the incidence of autoimmune disease, vascular thrombosis or other serious side-e ects. Of the deaths reported around the time of vaccination, none were considered to be associated with the vaccine.
Cost-e ectiveness of population-wide HPV vaccination in South Africa
A recent calculation of the cost-e ectiveness of introducing HPV vaccination in South Africa (Sinanovic, 2009) found that the price for the vaccine was the main cost driver. A price reduction of 60% or more would make vaccine-plus-screening more cost e ective than the screening-only option.
Ideal age of vaccination
Most authorities have recommended that HPV vaccination should be routinely o ered to females between 11 and 12 years, but it can be administered as young as nine years. Catch-up vaccination is recommended for females aged 13 to 26 years who have not been previously vaccinated.
Data are now available to support that there is signi cant clinical e cacy with Gardasil® vaccination in women up to 45 years of age, and immunogenic e cacy with Cervarix® in women up to 55 years of age.
Testing before vaccination
Testing for HPV exposure before vaccination is currently not recommended. In general, no additional testing is required before vaccination, except where pregnancy may be a possibility.
The HIV pandemic
Studies on HPV immunisation in HIV-infected individuals are not readily available. The e cacy of HPV vaccination in immunocompromised individuals is largely unknown.
Recommendations for implementation of HPV vaccines in SA
Population-wide HPV vaccination
In South Africa, an HPV immunisation programme should be planned, in order to reduce the cervical cancer epidemic. A coverage rate of over 70% is needed to impact on cervical cancer incidence. While this is a public health issue that should be addressed by Government, the South African Human Papillomavirus Advisory Board makes the following recommendations:
• Universal immunisation of young girls before the age of sexual debut. • Vaccination should be between nine and 12 years.
• Both available vaccines require a multi-dosing schedule; three doses are recommended at months 0, 1-2 and 6.
Individual HPV immunisation before populationwide HPV vaccination
• Teenaged females: Immunisation of young females, up to the age of 26 years, on an ad hoc basis is recommended. The prerequisites for this practice include a consenting, well-informed patient, nancial a ordability, and information on cervical screening in future.
• Adult females: Neither HPV DNA testing of the cervical area, nor serological HPV antibody testing, proves non-contact with HPV. The entire adult female population should not be a primary target group for vaccination, although individuals may bene t from vaccination.
• Males: Routine vaccination of the male population is not currently recommended. However, individuals may bene t from vaccination and, in future, coste ectiveness may be shown for disease prevention in men and/or women.
• High risk subgroups: It is di cult to de ne and identify high-risk individuals. Not all individuals who are at high risk of HPV infection may bene t from HPV vaccination, although some individuals may. These groups should be targeted for genital cancer screening.
• HIV-positive individuals: Individuals who are infected by HIV are at an increased risk of developing HPVrelated cancers. A patient with an intact immune system can potentially bene t from vaccination, and this is considered a safe approach. However, in women with AIDS, the immune response will probably be insu cient.The importance of regular screening is obvious.
• Post-exposure vaccination: Unless proven ine ective in further studies, immediate vaccination of rape survivors should be strongly considered.
Contraindications to vaccination
The safety of HPV vaccination in pregnancy has not been established. While initial trials reported no adverse e ects, single reports on vaccine reactions and side-e ects are appearing in the literature. These vaccines are, however, regarded as extremely safe.
Prophylactic vaccines used for therapeutic e ect
There is insu cient evidence of a therapeutic bene t of the available prophylactic HPV vaccines in individuals with established infection or disease, and this usage is currently not recommended.
Cervical cancer screening tests in conjunction with HPV vaccination
Continued cervical cancer screening will be needed for many decades to come. Not only will su cient population coverage take many years to be achieved, but all women, and particularly immunocompromised women, will require ongoing screening in an ideal health care system.
The public health sector should, as a matter of urgency and priority, continue to implement the current cytological screening programme. It is also recommended that the age of rst smear should be shifted to the left, probably to age 25. The South African Human Papillomavirus Advisory Board previously also recommended that Government should explore alternative screening strategies, including HPV testing.
Cytology and HPV vaccination
HPV vaccination in women with existing cytological anomalies has no bene t. Cytology, as a prerequisite before vaccination, is also not recommended. Cytological screening of HPV-vaccinated women is recommended and required, as protection is not 100%.
HPV testing and HPV vaccination
HPV DNA or antibody testing prior to vaccination is not recommended to prove or disprove prior HPV exposure. HPV antibody testing has no current clinical application and need not be performed to prove an immune response.
The use of HPV DNA testing as a primary screening test may be more appropriate in the vaccine era and, as triage with cytology, will still be an applicable screening option in the post-vaccination era. (See recommendations by the South African Human Papillomavirus Advisory Board ).
The South African Human Papillomavirus Advisory Board was established in August 2005 as an independent advisory group of clinicians and scientists, considered to be opinion leaders in the eld of gynaecological oncology and cervical cancer epidemiology and screening. The Board is a liated to SASOG and SASGO and is supported logistically by several companies with an interest in HPV-related disease. The members of the Board do not declare any con ict of interest. The opinions and recommendations expressed in this document do not re ect the policy of any company or the opinion of any individual board member, and is not meant to be prescriptive or legally binding.
These guidelines are intended and presented as summarised information for health care providers and managers, interpreted with South African data and conditions in mind, on which to base clinical decision making. This document represents the rst major revision of the vaccine document published in 2008 and will continue to be revised. For the references of this guideline summary, please consult the webpage of SAJGO.
